Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
ACA, accidental, Activyl, Afferent, allogeneic, altrenogest, Aquavac, Aralez, argument, Atozet, attached, Avirulent, background, Bacterin, baterin, bench, Betamethasone, bill, Biopharma, Cabilly, carboplatin, carcinoma, CDI, CENCOEX, clarified, clarify, classical, cleaving, cloprostenol, Clotrimazole, CMS, CMV, Cogan, declaratory, degradation, DICOM, DIPRO, earliest, eDMC, element, Emamectin, entail, fenbendazole, florfenicol, flunixin, Genentech, Gentamicin, Gilead, graduated, Green, Harvoni, hepatocellular, HNSCC, Hodgkin, Hope, HTA, Hyopneumoniae, idiopathic, impracticable, inactive, India, ineligible, kind, Lancet, Lawsonia, learned, lease, legislature, Levitra, licensor, lovastatin, Magistrate, Marek, Marrow, MCM, mediastinal, meglumine, messenger, Mexico, Misuse, Moderna, Mountain, multicenter, Mycoplasma, nasopharyngeal, NAV, neurogenic, norfloxacin, Northern, Ohio, Orbifloxacin, Otic, Otomax, overturn, page, Panacur, payer, PDL, pemetrexed, porcine, pre, PRIME, PTE, qui, reallocate, recast, reconciling, refractory, relapsed, repeal, Roxane, ruzasvir, score, simplify, sofosbuvir, Solvadi, spanning, SPC, StayWell, steadily, stem, student, substitute, sulfate, suppression, tam, Tildipirosin, TPS, transparency, trenbolone, unsuccessful, untreated, uprifosbuvir, urothelial, USP, valerate, Vector, Vermont, Vestar, visit, voted, withheld, zilpaterol, zinc, Zinplava
Removed:
acid, affirming, aggressively, agree, alfa, allegedly, announce, answered, antihistamine, API, approving, Aspen, assisted, atherothrombotic, Austria, BACE, Bank, base, Basic, Becton, begun, Belgium, blockade, Brazilian, break, bulk, call, capped, CDC, certiorari, Clarinex, community, confident, Congressional, constipation, Conversely, corifollitropin, coronary, Cosopt, DEESE, density, desloratadine, devalued, Dickinson, dipeptidyl, Dodge, downplayed, Dr, economically, Eldon, elevated, enable, enactment, enhance, entirety, Eurofarma, evolution, exclusively, exhausted, failed, Fallon, feed, finalized, finasteride, fiscal, formula, Fort, Fosavance, FTC, function, Gleeson, hair, home, hormonal, incremental, induced, Inhibition, injunction, inspection, internationally, investor, ipilimumab, John, joined, lesser, lieu, Louisiana, lump, manner, minimize, Ministry, Missouri, morbidity, mortality, move, Mylan, nonforfeitable, Obama, obesity, offshore, oversaw, Parenteral, pattern, PF, Pisano, placebo, Portugal, posed, predetermined, predicting, prefilled, preladenant, presenting, prevented, prioritization, protease, rapidly, remanded, remeasurement, repricing, reproductive, retainer, retired, retroactively, revocation, rheumatoid, rocuronium, rosenblatt, routinely, Sandoz, selectively, sharpen, SICAD, similarly, Spanish, specialty, stay, stimulation, Supreme, Sweden, syringe, Taxpayer, territorial, thromboembolism, tildrakizumab, triple, Trusopt, uncured, undertaken, unrepatriated, utilize, vacated, vecuronium, venued, view, voice, voluntary, VTE, waive, WILLIE, withdrawal, withdrew, Wyeth
Filing tables
Filing exhibits
- 10-K Annual report
- 10.2 Exhibit 10.2: Deferral Program Document (Amended & Restated 12/1/15)
- 10.19 Exhibit 10.19: 2016 Nqso Grants Under Merck & Co., Inc. 2010 Incentive Stock PLN
- 10.20 Exhibit 10.20: 2016 Rsu Grants Under Merck & Co., Inc. Incentive Stock Plan
- 10.21 Exhibit 10.21: 2016 Psu Award Terms Under Merck & Co., Inc. 2010 Stock Incentive
- 10.24 Exhibit 10.24: Merck & Co., Inc. U.S. Separation Benefits Plan Eff 01/01/17
- 12 Exhibit 12: Computation of Ratios of Earnings to Fixed Charges
- 21 Exhibit 21: Subsidiary List
- 23 Exhibit 23: Consent of Independent Registered Public Accounting Firm
- 24.1 Exhibit 24.1: Power of Attorney
- 24.2 Exhibit 24.2: Certification of Board Resolution
- 31.1 Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification of CEO
- 31.2 Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification of CFO
- 32.2 Exhibit 32.2: Section 1350 Certification of CFO
- 32.2 Exhibit 32.2: Section 1350 Certification of CFO
- Download Excel data file
- View Excel data file
Related press release
MRK similar filings
Filing view
External links
Exhibit 32.2
Section 1350
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 28, 2017 | /s/ Robert M. Davis | |
Name: ROBERT M. DAVIS | ||
Title: Executive Vice President, Global Services and Chief Financial Officer |